Research Paper Volume 15, Issue 5 pp 1628—1651
Integrative analysis to screen novel pyroptosis-related LncRNAs for predicting clinical outcome of glioma and validation in tumor tissue
Figure 6. Predicting patient prognosis in the TCGA cohort based on PRLPM. (A) Regression coefficient profiles of identified pyroptosis immune regulators in the TCGA cohort. (B) Ten-time cross-validation for tuning parameter selection in the TCGA cohort. (C) Patients were divided into high and low-risk subgroups according to median level of PRLPM riskscore in train set; heatmap of 9 PRLs. (D) multivariate cox regression analyses of the association between PRLs and OS of patients in the TCGA cohort. (E) KM curve plot of OS for patients in high and low-risk subgroups. (F, G) Survival analyses for subgroup patients stratified by both PRLPM riskscore and treatment with radiotherapy (F) and pharmacological chemotherapy (G) in the TCGA cohort. (H) The timeROC curve to evaluate the prognostic value of PRLPM riskscore in TCGA cohort.